通过机器学习发现β2上腺素受体的强大和多样化的激动剂
Siyao Zhang1,2, Chenyang Wu1,2, Shiyu Wang3
1Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.
ACS pharmacology & translational science
|December 18, 2025
概括
研究人员使用机器学习选了1900万种化合物,以寻找新的β2上腺素受体 (β2AR) 对呼吸系统疾病的激动剂. 他们发现了强大的,结构多样化的激动剂,有可能提高药物的安全性和有效性.
科学领域:
- 药物的发现和开发.
- 计算化学和化学信息学
- 药理学和药物化学 药理学和药物化学
背景情况:
- 多种化合物查对新药发现至关重要,提供专利导航和毒性避免等优势.
- G蛋白结合受体 (GPCR) 是关键的药物点,β-2上腺素受体 (β2AR) 是呼吸系统疾病治疗的重要点.
- 现有的β2AR激动剂需要优化以提高安全性,疗效和选择性.
研究的目的:
- 开发和应用机器学习 (ML) 和计算方法,以有效选大型复合库.
- 确定针对β2AR的新型,强效和结构多样化的激动剂.
- 为了解决改善呼吸道疾病治疗剂的需求.
主要方法:
- 利用机器学习 (ML) 与计算方法集成,用于高通量选.
- 选了一个包含1900万种化学化合物的综合图书馆.
- 通过细胞功能检测验证已识别的激动剂.
主要成果:
- 确定了几种具有高强度β2AR激动剂,EC50值范围从0.2到20nM.
- 发现了具有新型化学结构的激动剂,与以前报告的分子不同.
- 通过实验验证确认了已识别的化合物的疗效.
结论:
- 机器学习和计算查为发现新型GPCR候选药物提供了强大的策略.
- 鉴定出的强效和结构多样化的激动剂代表了开发下一代β2AR疗法的有希望的线索.
- 这种方法加速了针对GPCR目标的新药候选剂的设计,解决未满足的医疗需求.
相关概念视频
Adrenergic Receptors: β Subtype
3.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.4K
Adrenergic Agonists: Direct-Acting Agents
2.6K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.6K
Drug-Receptor Interaction: Agonist
3.7K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K


